Pharmacodynamics of taxol in human head and neck tumors

Cancer Research

Volumn 56, Issue 9, 1996, Pages 2086-2093

  Gan, Yuebo ^a   Wientjes, M Guillaume ^a,c   Schuller, David E ^b,c   Au, Jessie L S ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; PACLITAXEL;

APOPTOSIS; ARTICLE; CELL INTERACTION; CYTOARCHITECTURE; DNA SYNTHESIS INHIBITION; DRUG EFFECT; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; TUMOR RESISTANCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PACLITAXEL; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029877212     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Arbuck, S G., and Blaylock, B. A Taxol: clinical results and current issues in development. In: M. Suffness (ed ), Taxol: Science and Applications, pp. 379-415. Boca Raton, FL: CRC Press, 1995.
2. Forastiere, A. A Paclitaxel (taxol) for the treatment of head and neck cancer. Semin Oncol , 21. 49-52, 1994.
3. Horwitz, S. B Taxol (paclitaxel) Mechanism of action. Ann Oncol , 5: 53-56, 1994.
4. Crossin, K. L., and Carney, D. H. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and epidermal growth factor. Cell, 27. 341-350, 1981.
5. Liu, Y., Bhalla, K., Hill, C , and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol , 48: 1265-1272, 1994.
6. Bhalla, K., Ilerado, A. M , Tourkina, E., Tang, C., Mahoney, M. E., and Huang, Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia (Baltimore), 7: 563-568, 1993.
7. Milas, L., Hunter, N. R., and Kurdoglu, B Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol Cancer Chemother. Pharmacol., 35, 297-303, 1995.
8. Li, X., Gong, J., Felman, E., Seiter, K , Traganos, F., and Darzynkiewicz, Z. Apoptotic cell death during treatment of leukemias. Leuk. & Lymphoma, 13: 65-70, 1994.
9. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J., and Yang, C. P. H. Taxol. Mechanisms of action and resistance J. Natl Cancer Inst., 15: 55-61, 1993.
10. Roy, S., and Horwitz, S B. A phosphoglycoprotein associated with taxol-resistance in J774 2 cells Cancer Res , 45: 3856-3863, 1985.
11. Speicher, L. A , Barone, L. R., Chapman, A. E., Hudes, G. R., Laing, N., Smith, C. D , and Tew, K. D. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estromustine. J. Natl Cancer Inst., 86: 688-694, 1994.
12. Bhalla, K., Huang, Y., Tang, C , Self, S., Ray, S., Mahoney, M. E , Ponnathpur, V., Tourkina, E., Ibrado, A. M., and Bullock, G. Characterization of a human myeloid cell line highly resistant to taxol Leukemia (Baltimore), 8: 465-475, 1994.
13. Mickisch, G. H., Licht, T , Merlino, G. T., Gottesman, M. M., and Pastan, I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res , 51: 5417-5424, 1991.
14. Jachez, B , Nordmann, R., and Loor, F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl. Cancer Inst., 85: 478-483, 1993.
15. Lenert, M., Emerson, S., William, S. D., de Giuli, R., and Salmon, S. E. In vitro evaluation of chemosensitizers for clinical reversal of p-glycoprotein-associated taxol resistance. J. Natl. Cancer Inst. Monogr , 15: 63-67, 1993.
16. Peoc'h, M , Brambilla, E , Moro, D., Gazzeri, S., and Brambilla, C. Respective roles of the products of the mdr1 and p53 genes in drag resistance of bronchial cancers. Bull. Cancer, 81 (Suppl ): 98s-104s, 1994.
17. Riva-Lavieille, C. Chimioresistance, oncogenes et anti-oncogenes dans les tumeurs epitheliales. Bull. Cancer, 81 (Suppl.). 105s-111s, 1994.
18. Wattel, E , Preudhomme, C., Hecquet, B., Vanrumbeke, M , Quesnel, B., Dervite, I. Morel, P., and Fenaux, P p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies Blood, 84: 3148-3157, 1994.
19. Hickman, J. A , Potten, C. S , Merritt, A. J , and Fisher, T. C Apoptosis and cancer chemotherapy Philos. Trans. R Soc. Lond. B Biol Sci , 345: 319-325, 1994.
20. Reed, J C , Kitada, S., Takayama, S., and Miyashita, T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines Ann. Oncol , 5, 61-65, 1994
21. Dole, M , Nunez, G., Merchant, A. K , Maybaum, J , Rode, C. K., Bloch, C. A., and Castle V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma Cancer Res., 54: 3253-3259, 1994.
22. Weller, M., Malipiero, U., Aguzzi, A., Reed, J. C , and Fontana, A. Proto-oncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest., 95: 2633-2643, 1995.
23. Kitada, S , Takayama, S., De Riel, K., Tanaka, S., and Reed, J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev., 4, 71-79, 1994.
24. Fisher, D E. Apoptosis in cancer therapy, crossing the threshold. Cell, 78: 539-542, 1994
25. Yonish-Rouach, E., Resnitzky, D , Lotem, J , Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interteukin-6. Nature (Lond.), 352: 345-347, 1991.
26. Lowe, S W., Ruley, H E , Jacks, T., and Housman, D E p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell, 74: 957-967, 1993.
27. Lee, J. M., and Bernstein, A. p33 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci USA, 90: 5742-5746, 1993.
28. Lowe, S. W , Bodis, S , McClatchey, A , Remington, L., Ruley, H E., Fisher, D. E., Housman, D. E., and Jacks, T P53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266. 807-810, 1994.
29. McDonnell, T. J., Mann, M. C., Hsu, B., Brisbay, S. M., McConnell, K., Tu, S. M., Campbell, M. L., and Rodriguez-Villanueva, J. The bcl-2 oncogene, apoptosis and neoplasia. Radiat. Res., 136. 307-312, 1993
30. Vesico, R A , Redfern, C. H., Nelson, R J., Ugoretz, S , Stern, P. H., and Hoffman, R M In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl. Acad. Sci. USA., 84: 5029-5033, 1987.
31. Au, J L-S., Wientjes, M. G., Rosol, T J., Koolemans-Beynen, A , Goebel, E A., and Schuller, D. E. Histocultures of patient head and neck tumors for pharmacodynamics studies. Pharmacol Res., 10: 1493-1499, 1993.
32. Kohler, D. R., and Goldspiel, B. R. Paclitaxel (taxol). Pharmacotherapy, 14. 3-34, 1994.
33. Kerr, J. F. R , Clay, M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
34. Gavrieli, Y., Sherman, Y , and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation J Cell Biol , 119: 493-501, 1992.
35. Takagi, S., McFadden, M. L., Humphreys, R E , Woda, B A., and Sairenji, T. Detection of 5-bromo-2-deoxyuridine (BrdUrd) incorporation with monoclonal anti-BrdUrd antibody after deoxyribonuclease treatment. Cytometry, 14: 640-648, 1993.
36. Toth, K., Vaughan, M. M., Slocum, H. K., Arredondo, M. A., Takita, H., Baker, R. M., and Rustum, Y. M. New immunohistochemical "sandwich" staining method for mdr1 p-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues. Am. J. Pathol., 144: 227-236, 1994.
37. Katagiri, A., Tomita, Y., Nishiyama, T., Kimura, M., and Sato, S. Immunohistochemical detection of P-glycoprotein and GSTP-1 in testis cancer. Br. J. Cancer, 68: 125-129, 1993.
38. Gerlach, J. H., Bell, D. R., Karakousis, C., Slocum, H. K., Kartner, N., Rustum, Y. M., Ling, V., and Baker, R. M. p-glycoprotein in human sarcoma, evidence for multidrug resistance. J. Clin. Oncol., 5: 1452-1460, 1987.
39. Pavelic, Z. P., Reisind, J., Pavelic, L., Kelley, D. J., Stambrook, P. J., and Gluckman, J. L. Detection of p-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch. Otolaryngol. Head & Neck Surg., 119: 753-757, 1993.
40. Derry, W. B., Wilson, L., and Jordan, MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry, 34: 2203-2211, 1995.
41. Robbins, K. T , Connors, K M., Storniolo, A. M., Hanchett, C., and Hoffman, R. M. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Arch. Otolaryngol. Head & Neck Surg., 120: 288-292, 1994.
42. Furukawa, T., Kubota, T., and Hoffman, R M. The clinical applications of the histoculture drug response assay. Clin. Cancer Res., 1: 305-311, 1995.
43. Kubota, T., Sasano, N., Abe, O., Nakao, I., Kawamura, E , Saito, T., Endo, M , Kimura, K., Hiroshi, D., Sasano, H , Nagura, H., Ogawa, N., Hoffman, R. M , and the chemosensitivity study group for the histoculture drug-response assay. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin. Cancer Res , 1: 1537-1543, 1995.
44. Lopes, N. M., Adams, E. G., Pitts, T. W., and Bhuyan, B. K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines Cancer Chemother. Pharmacol., 32: 235-242, 1993
45. Liebmann, J., Cook, J. A., Lipschultz, C., Teague, D., Fisher, J., and Mitchell, J. B. The influence of Cremophor EL on the cell cycle effects of paclitaxel (taxol) in human tumor cell lines. Cancer Chemother Pharmacol., 33 331-339, 1994
46. Donaldson K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.
47. Chiarugi, V., Masnelli, L., Cinelli, M , and Basi, G. Apoptosis and the cell cycle Cell. Mol. Biol Res., 40. 603-612, 1994
48. Yonish-Rouach, E., Grunwald, D , Wilder, S., Kimchi, A., May, E , Lawrence, J J., May, P., and Oren, M. p53-mediated cell death: relationship to cell cycle control. Mol. Cell Biol., 13. 1415-1423, 1993.
49. Havrileski, L. J., Elbendary, A., Hurteau, J. A., Whitaker, R. S , Rodriguez, G C., and Berchuck, A. Chemotherapy-induced apoptosis in epithelial ovarian cancers Obstet. Gynecol., 85: 1007-1010, 1995.
50. Li, C. J., Wang, C., and Pardee, A. B. Induction of apoptosis by β-lapachone in human prostate cancer cells. Cancer Res., 55: 3712-3715, 1995.
51. Ragland, B. D., Ashley, L. S., Vaux, D L., and Petri, W. A. Entamoeba histolitica: target cells killed by trophozoites undergo DNA fragmentation which is not blocked by bcl-2 Exp Parasitol , 79: 460-467, 1994.
52. Frankfurt, O S., Seckinger, D., and Sugarbaker, E. V. Pleiotropic drug resistance and survival advantage in leukemic cells with diminished apoptotic response. Int. J. Cancer, 59: 217-224, 1994
53. Haldar, S , Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation Proc Natl Acad. Sci. USA, 92: 4507-4511, 1995.